Dana Ault-Riché received his PhD in Biochemistry with Prof Ronald Borchardt at the University of Kansas and was a postdoctoral fellow with Professor and Nobel Laureate Arthur Kornberg at Stanford University. Dr Ault-Riché is a biotech entrepreneur based in San Francisco and has founded 5 different biotech companies: two technology-focused companies (Zyomyx and Pointilliste), one diagnostics company (Diazyme-General Atomics) and two pharmaceuticals-focused companies (AllChemie and Reflexion Pharmaceuticals).
Juan B. Blanco-Canosa holds a BSc and PhD degrees in Organic Chemistry from the University of Santiago de Compostela (2006) carried out under supervision of José L. Mascareñas. He was done a visiting research in the lab of Barbara Imperiali (MIT), and carried out a postdoc in the The Scripps Research Institute under supervision of Philip E. Dawson. Currently, he is a Ramón y Cajal Fellow at the Institute for Research in Biomedicine in Barcelona. His research interests cover the chemical synthesis of proteins including transcription factors and signaling pathway proteins, orthogonal bioconjugation and Quantum Dots nanotechnology. Juan B. has been awarded with Fulbright and Marie Curie fellowships and is a member of American Peptide Society and European Peptide Society. He is co-author of more than 41 publications in peer-reviewed journals.
INSTITUTE FOR RESEARCH IN BIOMEDICINE BARCELONA
UNIVERSITY OF LEIPZIG
Prof. Dr. Annette G. Beck-Sickinger undertook undergraduate and postgraduate studies at the University of Tübingen (Dipl. Biology, Dipl. Chemistry, Ph. D. Organic Chemistry) and post doctoral work at ETH Zürich and University of Copenhagen. She has held a guest professorship at Vanderbilt University and since 1999 is professor in Bioorganic Chemistry and Biochemistry at the University of Leipzig. Her research interests are focused on (1) structure-activity- relationships of peptide hormones and G protein coupled receptors and (2) protein modification to study function and interactions. A tight connection of chemical methods, bioorganic synthesis and molecular biology tools, including cloning, receptor mutagenesis, protein expression and cell biochemistry is applied. Whereas in the first field, the application goes towards medicinal chemistry, identification of novel targets and novel therapeutic concepts, the second field is related to biomaterials, novel approaches to modify proteins and concepts for improved enzyme catalysis.
Brian was born in Cape Town, South Africa. He received his B. Sc. (1969) and B. Sc. (Hons) (1970) from the University of Cape Town and D.Phil. (1976) in experimental nuclear physics from Oxford University. He is currently Camille and Henry Dreyfus Professor at Rockefeller University in New York, where he is Head of the Laboratory for Mass Spectrometry and Gaseous Ion Chemistry. He also directs the NIH-funded National Resource for the Mass Spectrometric Analysis of Biological Macromolecules. Professor Chait has received several awards for his research in developing instrumentation and methods for characterizing proteins, including the 2000 Bijvoet Medal, the 2002 ACS Field & Franklin Award for Outstanding Achievement in Mass Spectrometry, the 2007 HUPO 2007 Distinguished Discovery Award In Proteomics, the 2012 Per Edman Award, and the 2015 ASMS Award for a Distinguished Contribution in Mass Spectrometry. He has co-authored 391 publications (46,500 citations) and has been awarded 30 US patents
UNIVERSITY OF QUEENSLAND
David Craik is a group leader and Professor of Chemistry at the Institute for Molecular Bioscience at The University of Queensland, Brisbane, Australia. He obtained his PhD in organic chemistry from La Trobe University in Melbourne, Australia and undertook postdoctoral studies at Florida State and Syracuse Universities before taking up a lectureship at the Victorian College of Pharmacy in 1983. He was appointed Professor of Medicinal Chemistry and Head of School in 1988. He moved to University of Queensland in 1995 to set up a new biomolecular NMR laboratory and is currently an Australian Research Council Laureate Fellow.
His research focuses on the discovery and applications of circular proteins, toxins and NMR in drug design. He is a Fellow of the Australian Academy of Science and has received numerous awards for his research, including the Ralph F. Hirschmann Award from the American Chemical Society. He is author of 600 scientific papers (h-index 75, citations 21,000) and has trained 60 PhD students.
Dr. Currie has made critical scientific discoveries that have greatly advanced our understanding of the regulation of blood pressure and the balance of sodium and water in the body. These discoveries have played a role in finding novel treatments for a broad range of diseases including congestive heart failure, acute and chronic pain conditions associated with arthritis and more recently a novel approach to treat patients with painful GI conditions. Dr. Currie’s discoveries and efforts have help to improve the lives of patients throughout the world.
Mark serves as Ironwood Pharmaceuticals, Senior Vice President of Research and Development and Chief Scientific Officer. He has led the company’s R&D efforts since joining in 2002. Dr. Currie has over 30 issued US patents and is the primary inventor of linaclotide which is a 14 amino acid peptide that activates guanylate cyclase-c and is first in class and has been approved for the treatment of chronic idiopathic constipation and IBS-C in adults. Linaclotide is marketed in the US as Linzess and in Europe as Constella. The drug, which reduces abdominal pain and addresses large unmet need, has had 4 highly successful phase 3 trials in chronic constipation and irritable bowel syndrome (IBS). Linaclotide has the potential to markedly improve the treatment of IBS patients suffering from chronic abdominal pain.
Prior to joining Ironwood, he led discovery at Sepracor and pharmacology at Monsanto/Searle. These efforts produced several important medicines, including Celebrex and Lunesta.
Ratmir Derda received his undergraduate degree in Physics from Moscow Institute of Physics and Technology in 2001 and Ph.D. in Chemistry from the University of Wisconsin-Madison in 2008, under the supervision of Laura L. Kiessling. From 2008 to 2011, he was a postdoctoral researcher at Harvard University working under the supervision of George M. Whitesides and Donald E. Ingber. He joined University of Alberta in 2011 as an Assistant Professor in Chemistry. In 2012, he became a principal investigator at the Alberta Glycomics Centre. Derda lab is focused on development of genetically-encoded chemical libraries, selection and evolution of bioactive ligands with dynamic properties and investigation of fundamental mechanism in cell growth and differentiation. His notable awards include Young Investigator Award from the Boulder Peptide Society (2014), Canadian Rising Star in Global Health (2011).
UNIVERSITY OF ALBERTA
Professor David Fairlie is located in the Division of Chemistry and Structural Biology at the Institute of Molecular Bioscience, University of Queensland, Brisbane Australia. He was an undergraduate at the University of Adelaide, did postgraduate research in chemistry at the Australian National University in Canberra and University of New South Wales, postdoctoral research at Stanford University and University of Toronto. He has been an Australian Research Council Federation Fellow and Professorial Fellow and a Senior Principal Research Fellow of the Australian National Health and Medical Research Council. He is a Chief Investigator of the Australian Research Council Centre of Excellence in Advanced Molecular Imaging, which is aimed at understanding the molecular basis of immunity. He has founded and co-founded startup companies in Australia and North America and has consulted extensively with pharmaceutical companies in the USA and Europe. David’s research interests are at multiple interfaces of chemistry and biology, especially in drug discovery, medicinal chemistry, biochemistry, pharmacology and immunology. He has published over 350 journal articles in multiple branches of chemistry (medicinal, biological, organic, inorganic, computational) and biology (biochemistry, pharmacology, immunology, virology, neurobiology, oncology, parasitology) and has trained more than 100 postgraduate students.
UNIVERSITY OF QUEENSLAND
Shiroh Futaki obtained his Ph.D. in 1989 from Kyoto University, Japan. Following his appointment as a Research Associate and an Associate Professor at the University of Tokushima, he moved to Kyoto University in 1997. Meanwhile, he spent 16 months (1989-1991) in the US as a Postdoctoral Associate in the Department of Biochemistry, Rockefeller University. He has been a Professor of Biochemistry at the Institute of Chemical Research, Kyoto University, since 2005. His research interests include design of bioactive peptides having unique functions (cell penetration, DNA-binding, and so on). He has published more than 210 original research papers and 40 review publications in leading journals in peptide science and chemical biology. He is now appointed as the Vice President of The Japanese Peptide Society. He is also a member in the Board of Trustees of The Japanese Biochemical Society and the Editorial Boards of 4 scientific journals. His honor includes The Japanese Peptide Society Award for Young Scientists (1997) and The Pharmaceutical Society of Japan Award for Young Scientists (1998).
David received his undergraduate degree from Harvey Mudd College and his PhD in Chemistry from Yale University in the laboratory of Professor Sam Danishefsky. Following postdoctoral studies at the University of California, Berkeley, with Professor Clayton Heathcock, he joined Pfizer in 1995. There he has led Medicinal Chemistry efforts and broader Project Teams against targets for Obesity, Osteoporosis, and Diabetes resulting in multiple candidates advanced for clinical testing including the Ph3 CB-1 antagonist Otenabant. He is an author on more than 45 publications and is an inventor on 34 patents.
Sonia graduated with a degree in Biochemistry in 2003, and obtained a PhD in Molecular Biophysics in 2008 (University of Lisbon, Portugal). In 2008, Dr Henriques was awarded an ARC Australian Postdoctoral Fellowship and started her postdoctoral research at the University of Queensland at the Institute for Molecular Bioscience (IMB). In 2009, Dr Henriques was awarded a Marie Curie Fellowship and was appointed as invited lecturer in Portugal (Medicine School, University of Lisbon). Dr Henriques returned to IMB in 2012 upon reception of an ARC DECRA and she was subsequently awarded an ARC Future Fellowship in 2016. Dr Henriques research is focused on the study of membrane-active peptides, their mode of action at the cell membrane level, their potential use for drug design and/or as tools to deliver macromolecules into cells.
UNIVERSITY OF QUEENSLAND
Keliang Liu is a Professor at Beijing Institute of Pharmacology & Toxicology, Beijing, China. He obtained his PhD from Nankai University in 1988, and has subsequently worked at Beijing Institute of Pharmacology & Toxicology (Assistant Professor, 1988-1990), NIH (Visiting Fellow, 1990-1995), Beijing Institute of Pharmacology & Toxicology (Professor 1995-), Johns Hopkins University (Visiting Scientist, 1998-1999). Research Interests: (1) Bioactive peptide and peptide drug research, especially design and evaluation of new HIV-1 fusion inhibitors. (2) Research of nucleic acid therapeutics. (3) Biomaterials for pharmaceutical uses.
BEIJING INSTITUTE OF PHARMACOLOGY & TOXICOLOGY
Dr. Lara Malins is a National Institutes of Health Postdoctoral Fellow at the Scripps Research Institute in the laboratory of Professor Phil Baran. She began her career in chemistry at Boston University where she completed her undergraduate studies in chemistry in 2009. She relocated to The University of Sydney under the International Postgraduate Research Scholarship (IPRS) scheme to carry out her PhD on the development of chemoselective peptide ligation methods with Professor Richard Payne. Lara’s current research at Scripps focuses on the development of new strategies for peptide macrocyclization and the post-synthetic modification of peptides using metal-catalyzed, decarboxylative couplings.
SCRIPPS RESEARCH INSTITUTE
Associate Professor Mehdi Mobli is a Group Leader at the UQ Centre for Advanced Imaging. He is fascinated by peptide and protein structures, and is curious to find out how such molecules go about their daily life (dynamics) and perform their function in solution. He prefers disulfide rich peptides, in particular those that inhibit ion channels. Over the course of his research career, he has developed advanced NMR based approaches for investigating peptide-channel interactions. These require isotope enrichment, much to the dismay of his peptide-chemist colleagues. He was awarded an ARC Future Fellowship in 2011 and the Sir Paul Callaghan Medal in 2013 by Australian and New Zealand Society for Magnetic Resonance (ANZMAG).
UNIVERSITY OF QUEENSLAND
Tom W. Muir received his B.Sc in Chemistry in 1989 and Ph.D. in Chemistry in 1993 from the University of Edinburgh. After postdoctoral studies with Stephen B.H. Kent at the Scripps Research Institute, he joined the faculty at the Rockefeller University in New York City in 1996. In 2011, Dr. Muir joined Princeton University as the Van Zandt Williams, Jr. Class of ’65 Professor of Chemistry. He currently serves as Chair of the Princeton Department of Chemistry. He has published over 180 scientific articles in the area of chemical biology and is best known for developing methods for the preparation of proteins containing unnatural amino acids, posttranslational modifications and spectroscopic probes. These approaches are now widely employed in academia and industry. His currents interests lie in the area of epigenetics, where he tries to illuminate how chemical changes to chromatin are linked to different cellular phenotypes. Professor Muir has won a number of honors for his research, including; the Burroughs-Wellcome Fund New Investigator Award, the Pew Award in the Biomedical Sciences, the Alfred P. Sloan Research Fellow Award, the Leonidas Zervas Award from the European Peptide Society, the Irving Sigal Award from the Protein Society, the Vincent du Vigneaud Award in Peptide Chemistry, the Blavatnik Award from the New York Academy of Sciences, the Jeremy Knowles Award from the Royal Society of Chemistry, the Arthur C. Cope Scholar Award from the American Chemical Society, the Breslow Award in Biomimetic Chemistry from the American Chemical Society, and the E.T. Kaiser Award in Protein Chemistry from the Protein Society. Dr. Muir is a Fellow of American Association for the Advancement of Science, the Royal Society of Chemistry and the Royal Society of Edinburgh.
Professor Ray Norton holds a personal chair at the Monash Institute of Pharmaceutical Sciences, Melbourne. His lab employs a range of biophysical approaches, including NMR, SPR, ITC and X-ray crystallography, in studies of peptide and protein toxins and infectious diseases. One of the venom-derived peptides he works with is about to enter phase II clinical trial for autoimmune diseases. This range of biophysical methods is also applied in combined structure-based and fragment-based drug discovery programs directed at protein targets in the areas of infectious and parasitic diseases, graft rejection and metabolic diseases. He has published over 320 articles and is an inventor on 10 patents.
MONASH INSTITUTE FOR PHARMACEUTICAL SCIENCES
Chris is a Professor and Canada Research Chair in Protease Proteomics and Systems Biology, U.B.C. Vancouver. With 23 Nature Review, Science, and Nature/Cell/Science-sister journal papers (h-index 67), he is a pioneer of degradomics, a term he coined. He completed his Ph.D. at the University of Toronto; and post-doctoral work with Dr. Michael Smith, Nobel Laureate. In 1997/1998 was a Visiting Senior Scientist at British Biotech, Oxford and in 2004/2008 a Visiting Senior Scientist at Novartis, Basel, and is now an Honorary Professor, Albert-Ludwigs Universität Freiburg. Dr. Overall was 2002 CIHR Scientist of the Year, the UBC Killam Senior Researcher Award 2005, and was Chair of the 2003 MMP and the 2010 Protease Gordon Research Conferences. He was recognized by the IPS with the 2011 Lifetime Achievement Award; by the Matrix Biology Society of Australia and New Zealand with the 2012 Barry Preston Award; and in 2014 by the Tony Pawson Canadian National Proteomics Network Award for Outstanding Contribution and Leadership to the Canadian Proteomics Community. He is also an elected member of HUPO Executive Committee, the Chromosome Centric Human Proteome Project (C-HPP) Executive Committee, and is an Associate Editor of the Journal of Proteomics Research.
Dr. Alleyn Plowright obtained his PhD in organic chemistry with Professor Gerald Pattenden at the University of Nottingham in 1999, and continued with postdoctoral studies with Professor Andrew Myers at Harvard University. In 2002, he joined AstraZeneca where he led the medicinal chemistry efforts across a variety of drug discovery programs. In 2012, he became Senior Principal Scientist and Project Leader in the Cardiovascular and Metabolic Diseases Innovative Medicines unit leading multidisciplinary research and driving new projects into and through the drug project portfolio. In 2017 Alleyn moved to Sanofi, taking on the position as Head Integrated Drug Discovery Germany.
Matthew Pratt completed his B.S. in Biochemistry and Math from the University of Arizona in 1999 working with Robin Polt on the synthesis of glycopeptides. He then moved to UC Berkeley, receiving his Ph.D. in Chemistry with Carolyn Bertozzi, where he worked on the synthesis of complex carbohydrates and glycosyltransferase enzymatic activity. He then was a postdoc in the lab of Tom Muir at Rockefeller University working on the development of methods to control protein concentration in living cells. Matt began his independent career at USC in 2009 where his lab is interested in posttranslational modifications, in particular O-GlcNAc modification.
UNIVERSITY OF SOUTHERN CALIFORNIA
Dr. Uracha R. Ruktanonchai won a British council Scholarship and finished her Ph.D. in Pharmaceutical Sciences at the University Of Nottingham in 2002. During 2002-2003, she was a post-doc at School of Biomedical Sciences, Queen’s Medical center, University of Nottingham, working on Biomaterial research before taking up a researcher position at the National NanotechnologyCenter (NANOTEC), National Science and Technology Development Agency (NSTDA), Thailand in 2004. Currently, she is a Principal researcher and Director of Nanotechnology Research unit (NRU). Her research expertise is on encapsulation technology to control release and target bioactive compounds intended to be used for medical applications. Her research interest is in lipid dispersion, biocompatible polymeric nanoparticles and functionalized nanoparticles for Advance drug delivery system. Dr. Ruktanonchai has published research findings in more than 80 international publications with more than 20 patent applications. She also serves as an advisor, invited speaker and guest lecturer for various universities and conferences domestically and internationally. She was awarded a “Young Scientist of 2010” from the Foundation for the Promotion of Science and Technology under the Patronage of His Majesty the King, “2011 For Women in Science” fellowship from UNESCO L’Oreal Thailand. She was selected as one of “66 Young Leaders Shaping Thailand’s Future of 2012” by the Bangkok Post newspaper which celebrated its 66 years in operation, chosen as 1 of 10 prestigious keynote speakers of Top careers for 2020 “This’s My Future” (2009) organized by Thaikom foundation and 1 of 10 “prestige Women of the Year 2006” by Prestige magazine, The nation, and Bangkok Business. She has been selected to be a member of various foundations including Thai Academy of Science and Technology Foundation (TAST) and Thai Young Scientists Academy (TYSA). Only recently she was named a Fellow of the Royal Society of Chemistry (FRSC).
NATIONAL NANOTECHNOLOGY CENTRE
Balázs Sarkadi obtained his MD degree at Semmelweis Medical University, Budapest, in 1972, and his Ph.D. in 1980. He spent several years as a post-doc and then as a visiting scientist at major universities in the United States and Canada. He is research professor at Semmelweis University, member of the Hungarian Academy of Sciences, past president of the Federation of European Biochemical Societies (FEBS), member of several international research societies including ICRO and the Academia Europeae. His research has been focusing on membrane proteins, including the investigation of ABC membrane transporters, which play a major role in the multidrug resistance of cancer, in general pharmacology, and in stem cell function. His recent work is related to the generation and differentiation of stem cells for medical diagnostics and therapy. Balazs Sarkadi has published more than 220 papers in international scientific journals, with a citation number over 12,000.
Daniel Scott’s laboratory is focused on membrane protein engineering, structure and function. The foundation of the lab is the development of new, generic protein engineering methods that can be applied to facilitate the application of structural biology and structure based drug design to traditionally challenging membrane protein targets such as G protein-coupled receptors (GPCRs). After completing a PhD on the relaxin and INSL3 receptors at The University of Melbourne in 2007, Daniel worked as a postdoctoral researcher in the laboratory of Prof. Andreas Plückthun in Zurich, Switzerland. While in Zurich he invented a novel method, called CHESS, for the directed evolution of detergent-resistant membrane proteins. GPCRs stabilised with this method can be produced recombinantly in bacteria, purified in detergents and experimentally probed as if they were highly stable soluble proteins. Such stabilised GPCRs can be applied to X-ray crystallography and NMR for structural studies, but can also be used to probe the molecular determinants of ligand binding, ligand-receptor selectivity and for drug discovery. The CHESS technology was spun out into a Swiss biotechnology company, called G7 therapeutics, co-founded by Daniel in 2013. Daniel was recruited to The Florey in 2011 as a group leader, where he has engineered several peptide binding GPCRs to allow the biophysical characterisation of peptide binding and subsequent receptor activation.
FLOREY INSTITUTE OF
NEUROSCIENCE & MENTAL HEALTH
Martina Stenzel studied chemistry at the University of Bayreuth, Germany, before completing her PhD in 1999 at the Institute of Applied Macromolecular Chemistry, University of Stuttgart, Germany. She started as a postdoctoral fellow at UNSW in 1999 and is now a full Professor in the school of chemistry as well as co-director of the Centre for Advanced Macromolecular Design (CAMD)
Her research interest is focused on the synthesis of functional nanoparticles for drug delivery applications. Martina Stenzel published more than 230 peer reviewed papers mainly on polymer and nanoparticle design.
She is scientific editor of Materials Horizons and serves currently on a range of editorial boards. Furthermore, she was a member of the college of experts of the Australian Research Council (ARC). She received a range of awards including the 2011 Le Fèvre Memorial Prize of the Australian Academy of Science.
UNIVERSITY OF NEW SOUTH WALES
Professor Kristian Strømgaard graduated from the Royal Danish School of Pharmacy (1999), with part of the studies carried out at H. Lundbeck A/S and did his postdoctoral training at Columbia University (USA). He was appointed assistant professor at University of Copenhagen, and thereafter promoted to full professor in chemical biology 2006. His research spans chemistry and biology with focus on protein-protein interactions, and exploring these with peptide-based ligands. In 2014 he was appointed Director of Center for Biopharmaceuticals at University of Copenhagen. He is co-founder of the biotechnology company Avilex Pharma.
UNIVERSITY OF COPENHAGEN
UNIVERSITY OF BRISTOL
Prof Dek Woolfson took his first degree in Chemistry at the University of Oxford, UK. He then did a PhD at the University of Cambridge followed by post-doctoral research at University College London and the University of California, Berkeley. After 10 years as Lecturer through to Professor of Biochemistry at the University of Sussex, he moved to the University of Bristol in 2005 to take up a joint chair in Chemistry and Biochemistry. Dek’s research is at the interface between chemistry and biology, applying chemical methods and principles to understand biological phenomena. His group is interested in the challenge of rational protein design, and how this can be developed for synthetic biology. He places particular emphasis on making completely new protein structures and peptide-based biomaterials for applications in cell biology and medicine. In 2011, Dek became the first recipient of the Medimmune Protein and Peptide Science Award of the Royal Society of Chemistry; and in 2014 he received a Royal Society Wolfson Research Merit Award. Dek is Director of BrisSynBio, a £13.6M BBSRC/EPSRC-funded Synthetic Biology Research Centre.
Dr. Denise Wootten is a NHMRC Career Development Fellow working in the Drug Discovery Biology Theme at the Monash Institute of Pharmaceutical Sciences in Melbourne. Her expertise is in the study of G protein coupled receptors (GPCRs), particularly the family B subclass and the peptide ligands that activate them. The principal interest of her research is towards understanding the modes of their regulation in an effort to identify novel approaches for drug discovery. Her research interests encompass differential signalling via distinct peptide ligands, interaction of receptors with regulatory accessory proteins, allosterism and the structure and mechanism by which these GPCRs are activated. More recently, her work has also focused on addressing the link between in vitro pharmacology and signal transduction with the physiological effects elicited in vivo following peptide activation of these receptors.
MONASH INSTITUTE OF PHARMACEUTICAL SCIENCES
Professor Hanmei Xu is Head of The Engineering Research Center of Peptide Drug Discovery and Development. Her main research interests are: Design, screening and druggability evaluation of peptide drugs including anti-tumor, anti-rheumatoid arthritis, anti-pulmonary fibrosis and anti-acute inflammation drugs. Furthermore, improvement of peptide drug effectiveness by biochemical modifications, e.g. PEGylation, fusion with IgG Fc part, connection to HSA, etc. In the last five years she has published 59 papers, including 29 SCI papers about peptide science. Prof. Hanmei Xu is also an inventor of 39 patents, including 15 that have been granted about peptide science.
CHINA PHARMACEUTICAL UNIVERSITY
Tao Ye obtained his PhD from Queen's University, Belfast (QUB) (1993). After pursuing a post-doctoral stay (1993-1994) with Professor Tony McKervey at QUB, he moved to Nottingham University (1994-1998) as a "Realising our Potential Award" (ROPA) fellow to engage in the total synthesis of marine natural products, working with Professor Gerry Pattenden, FRS. He started his independent career in 1998, initially at The University of Hong Kong and then joined The Hong Kong Polytechnic University in 2001. In 2015, he moved to Peking University Shenzhen Graduate School where as a Professor of Chemical Biology and Senior PI. His research interests span the disciplines of natural product synthesis, chemical biology and drug discovery, which include the discovery and development of new agents of medicinal value through major advances in chemical synthesis. In addition to the completion of total synthesis of 46 natural products, he is well-known for contributions to the structural revision of the misassigned natural products. He received a "Xiaoyu Hu Memorial Award”, a “WuXi PharmaTech Life Science and Chemistry Award”, and has been admitted as a Fellow of the Royal Society of Chemistry.